UBS Group’s bioAffinity Technologies BIAF Stock Holding History

UBS Group’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20.4K	Buy	3,104 +2,824	+1,009%	+$24.4K	﹤0.01%	8483
2026 Q2	$3.41K	Sell	280 -334	-54%	-$10.2K	﹤0.01%	9193
2026 Q1	$35.3K	Buy	+614	New	+$14.9K	﹤0.01%	7592
2025 Q4	–	Sell	-10	Closed	-$423	–	10518
2025 Q3	$423	Buy	+10	New	+$1.19K	﹤0.01%	9683
2025 Q2	–	Hold	0	–	–	–	10162
2024 Q3	–	Sell	-21	Closed	-$20.7K	–	9506
2024 Q2	$20.7K	Buy	+21	New	+$21.8K	﹤0.01%	7279
2023 Q4	–	Hold	0	–	-$76	–	9316
2023 Q3	–	Hold	0	–	–	–	8938
2023 Q2	–	Sell	-5	Closed	-$4.14K	–	8426
2023 Q1	$4.55K	Sell	5 -10	-67%	-$8.68K	﹤0.01%	8174
2022 Q4	$10.5K	Buy	15 +4	+36%	+$4.56K	﹤0.01%	8499
2022 Q3	$14K	Buy	+11	New	+$20.8K	﹤0.01%	7893

Other funds holding BIAF

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

UBS Group's BIAF Position: Q3 2026 in Review

UBS Group increased its bioAffinity Technologies (BIAF) stake by 1,009% in Q3 2026, buying an estimated $24.4K and bringing the position to 3,104 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #8483.

UBS Group first reported a position in BIAF in Q3 2022 and has held it in 8 quarters since. The position peaked at $35.3K in Q1 2026. 5 funds tracked by Wall St. Rank hold BIAF as of Q3 2026.

UBS Group held 3,104 shares of bioAffinity Technologies worth $20.4K as of Q3 2026.
UBS Group bought 2,824 bioAffinity Technologies shares in Q3 2026, an estimated $24.4K.
bioAffinity Technologies made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8483 holding.
UBS Group first reported a position in bioAffinity Technologies in Q3 2022 and has held it in 8 quarters since.
UBS Group's bioAffinity Technologies position peaked at $35.3K in Q1 2026.
5 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.